San Francisco, October 15, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced that it was presenting at the BIO Europe in Hamburg.
Read MoreRecardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Now Enrolling and Recruiting in All Global Centers
San Francisco, September 9th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and US centers.
Read MoreRecardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Enrolling and Recruiting in Global Centers
San Francisco, June 19, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in multiple European and US centers.
Read MoreFirst Closings of Series B Financing Round
San Francisco, June 3rd, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases, announced the first closings of its Series B financing round.
Read MoreRecardio presented at the Cell & Gene Therapy Conference in New York
San Francisco, March 21, 2019 – Recardio announced today that it presented at the Cell & Gene Therapy Conference in New York.
Read More